While the β-cells of the endocrine pancreas are defined as cells with high levels of insulin production and tight stimulus-secretion coupling, the existence of functional heterogeneity among them has been known for decades. Recent advances in molecular technologies, in particular single-cell profiling on both the protein and messenger RNA level, have uncovered that β-cells exist in several antigenically and molecularly definable states. Using antibodies to cell surface markers or multidimensional clustering of β-cells using more than 20 protein markers by mass cytometry, 4 distinct groups of β-cells could be differentiated. However, whether these states represent permanent cell lineages or are readily interconvertible from one group to another remains to be determined. Nevertheless, future analysis of the pathogenesis of type 1 and type 2 diabetes will certainly benefit from a growing appreciation of β-cell heterogeneity. Here, we aim to summarize concisely the recent advances in the field and their possible impact on our understanding of β-cell physiology and pathophysiology. By definition, all adult β-cells express high levels of insulin, which is released in response to appropriate stimuli to help maintain blood glucose homeostasis. The primary secretagogue for β-cells is glucose, and the set-point and response curve for glucose are determined by the expression of the low affinity glucokinase enzyme instead of hexokinase in these cells. However, in vivo multiple other factors contribute to control the net insulin secretion of β-cells, among them amino acids, hormones, fatty acids and neuronal input. While for convenience' sake it is often assumed that all β-cells respond to these inputs equally, evidence for functional heterogeneity among β-cells was in fact already reported in the 1980s by Salomon and Meda, who were able to study the response of rat β-cells to glucose on the single-cell level using the reverse hemolytic plaque assay.
| INTRODUCTION
We have known for decades that not all β-cells are equal, but the analytical tools to identify inherent variation in β-cell function and health have been limited. Through technological advances, it is now possible to interrogate single cells at the DNA, mRNA, protein and functional levels. Recent discoveries show that human β-cells exist in multiple subtypes and that islet cell types can interconvert in type 2 diabetes (T2D). These findings raise the question whether the relative abundance of functionally distinct subpopulations vary in the glucose intolerant state or in diabetes, whether the different subtypes have unique antigenic properties in the context of type 1 diabetes (T1D), and to what extent and at which rate the different β-cell subpopulations are interconvertible. These questions are not academic, because their answers will provide insights into the pathophysiology of T1D and T2D, and will probably be relevant in our search for novel targets for therapeutic intervention.
By definition, all adult β-cells express high levels of insulin, which is released in response to appropriate stimuli to help maintain blood glucose homeostasis. The primary secretagogue for β-cells is glucose, and the set-point and response curve for glucose are determined by the expression of the low affinity glucokinase enzyme instead of hexokinase in these cells. However, in vivo multiple other factors contribute to control the net insulin secretion of β-cells, among them amino acids, hormones, fatty acids and neuronal input. While for convenience' sake it is often assumed that all β-cells respond to these inputs equally, evidence for functional heterogeneity among β-cells was in fact already reported in the 1980s by Salomon and Meda, who were able to study the response of rat β-cells to glucose on the single-cell level using the reverse hemolytic plaque assay. 1 In quick succession, multiple studies confirmed and extended these findings, [2] [3] [4] [5] was established among subnetworks of β-cells. Importantly, these β-to β-cell connections were inhibited by the addition of high concentrations of free fatty acids, simulating lipotoxicity. Importantly, the β-cell response to GLP-1 was inversely correlated with body mass index, suggesting that β-cell connectivity might play a role in the pathogenesis of T2D. While these studies showed altered β-cell behaviour given changing metabolic conditions, they did not directly address β-cell heterogeneity.
A critical question regarding the functional coupling of β-cells is whether the β-cell networks consists of equivalent β-cells which all have the same impact on the timing of the Ca 2+ oscillation, or if a hierarchy exists between certain "pacemaker" and "follower" β-cells, and thus true functional heterogeneity. Rutter et al recently addressed this issue using elegant optogenetic methods to determine that islet cells contain a small minority (less than 10% of β-cells) that when silenced disrupt β-cell networks, while calcium dynamics and insulin secretion where not affected when "follower" β-cells were silenced. 7 They concluded that the minority "hub" cells establish long-range connectivity to control and synchronize the remaining 
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A different approach for the study of β-cell heterogeneity, this time in human islets, was taken by Grompe's group, who screened for cell surface antibodies that could subdivide β-cells in fluorescence activated cell sortin (FACS) analysis. 11 Using this approach, they discovered that human β-cells elaborate different levels of the cell surface proteins ST8SIA1 and CD9, and can therefore be sorted into 4 subpopulations. Importantly, the relative abundance of the various subtypes depended on metabolic state, with different frequencies being observed in T2D. Thus, it is possible that the diabetic state causes a redistribution of β-cell subtypes, or even that altered subtype patterns contribute to the aetiology of T2D. It is important to note that at present it is unknown if these β-cell subtypes represent stable or semi-stable cell types or more rapidly interchangeable
states. This key question in the field of human β-cell heterogeneity will have to be addressed using advanced lineage tracing. In the case of the mouse, it is clear, however, that Fltp-negative cells can convert to Fltp-positive cells over time. 9 The studies described above all have in common that they begin with a specific functional property of the β-cell-that is, calcium currents-or the expression levels of preselected makers-that is, Flattop, CD9 or ST8SIA1. Thus, it is probable that unbiased, genomewide approaches will uncover β-cell heterogeneity to unprecedented Because these rare transcripts will-by chance-be captured in some cells but not in others, this can lead to an artefactual overestimation of heterogeneity among cells in a given population. It is expected that the efficacy of reverse transcription and initial amplification will be improved in the near future to minimize the impact of this issue.
In addition, by computationally combining rare transcripts into gene sets, groups of genes can be assessed more accurately. Nevertheless, depending on methodology, up to 5000 high and medium abundance mRNAs can be captured routinely even today, allowing single-cell analysis with exceptional detail. There is an obvious trade-off between the depth of sequencing per cell and the number of cells analysed in each single-cell transcriptome study, which will depend on the specific question to be answered in each experiment.
Over the past 2 years, several groups have employed single-cell RNA sequencing (scRNAseq) technologies to the analyses of mouse and human islets. Li et al 19 were the first to publish single-cell RNA sequencing, but only on 70 human islet cells. Thus, while they were able to determine the expression of known marker genes such as insulin and pre-pro-glucagon to determine major cell types, the number of cells analysed was too limited to characterize cell subtypes.
This study was quickly followed by single-cell transcriptomic publica- We generated single-cell transcriptomes of high-sequencing depths from multiple organ donors, including children, adults, T1D and T2D. 27 The high-sequencing depth allowed us to discovered many islet cells that display divergent expression patterns within each canonical endocrine cell type. Importantly, we found that insulin transcript levels can vary by more than 100-fold in human β-cells, an effect that would be difficult to capture using immunostaining methods (Figure 2 ). In a rare replicating α-cell, we found that multiple genes of the hedgehog signalling pathway were activated, showing how single-cell transcriptomics can implicate novel regulatory pathways in islet cell biology.
Perhaps most strikingly, we found that in α-and β-cells from T2D, the gene expression profiles of juvenile endocrine cells were reacquired, suggesting a partial dedifferentiation process.
A topic of much discussion is the issue of islet cell plasticity, or the degree and frequency with which one adult endocrine cell type can convert into another. Data from mouse models, for instance, with forced overexpression of key transcriptional regulators, have clearly
shown that islet cells can be forced to change fate. 28 One would we cannot see into the future and predict what we will find when we study the molecular heterogeneity of the human endocrine pancreas in ever increasing detail, one thing is certain: we are entering an exciting new phase of discovery in islet biology.
